

## ACP Trainees Weekend: Speaker Biographies

Saturday 11 November & Sunday 12 November 2023

### Dr Ik Shin Chin

✕ @IkShinChin1



Dr Ik Shin Chin is a Birmingham Centre Cancer Research UK (CRUK) Clinical Research Fellow and medical oncology registrar based in West Midlands. Her PhD research project focused on the identification of genetic factors predisposing towards chemotherapy and immunotherapy toxicity at the University of Birmingham, of which she is an investigator of the NIHR adopted ICI GENETICS multicentre UK study. She is also a steering committee member of the ECMC Junior Investigator Network. Her main research interests include cancer genetics, immuno-oncology and biomarker discovery.

### Dr Jenny Cotton



Jenny is a medical oncology registrar at the Clatterbridge Cancer Centre in Liverpool. She attended medical school at the University of St. Andrews completing a BSc in Medical Sciences before completing her medical degree at the University of Manchester. She completed academic foundation training at University Hospitals of Morecambe Bay NHS Foundation Trust before completing core medical training in the Mersey deanery. She took a special interest in oncology and palliative care during training and went on to work at Hospice West Auckland and Hospice North Shore in New Zealand before taking up a post at The Christie NHS Trust in Manchester, prior to starting her oncology training in Liverpool. She has an interest in medical leadership and has completed the Chief registrar programme under the RCP and now is chair of the sub-committee for trainees under the Association of Cancer Physicians.

### Dr Seamus Coyle



Seamus is a Consultant in Palliative Medicine at The Clatterbridge Cancer Centre and an Honorary Senior Clinical Lecturer at the Liverpool Head and Neck Centre at the University of Liverpool. He moved to Liverpool to take up an Academic Clinical Fellowship in August 2012 and completed consultancy training in 2016. His main research area is the Biology of dying and the development of a urine test to predict dying (recently patented) that he have been working on since moving to Liverpool. He is the Clinical lead for Innovation at Clatterbridge since February 2022.

### Professor Helena Earl



Helena Earl holds an Emeritus position as Professor of Clinical Cancer Medicine in the Department of Oncology, University of Cambridge. In 1992 she was appointed as a Senior Lecturer at the University of Birmingham where she was also Hon. Director of the Birmingham Cancer Research UK Clinical Trials Unit. She was appointed at the University of Cambridge, Department of Oncology in 1996. She has led multi-centre randomised clinical trials in breast cancer (NEAT, tAnGo, Neo-tAnGo, ARTEMIS, PERSEPHONE, and PARTNER). She has authored over 200 peer-reviewed papers, and held collaborative grant funding from Cancer Research UK, the NIHR HTA, with pharmaceutical partnership funding (Roche, Astra Zeneca, Sanofi-Aventis, Eli Lilly), with a career total of over £32m. She has also contributed as a national leader in Medical Oncology specialty training, and its development as an academic specialty in the UK over the past 30 years. She was appointed Hon President of ACP in January 2021. She is involved in the Lancet Commission Breast Cancer: tackling a global health, gender, and equity challenge, in line with her interests in Global Oncology.


### Dr Ashling Lillis



Ashling is a Consultant in Acute Medicine and Ambulatory Care at Whittington Health NHS Trust in North London. She joined Macmillan in 2016 as an NHS National Medical Director's Fellow. She continues to work with Macmillan as a National Clinical Advisor focusing on the experience of acutely unwell cancer patients and the importance of generalist expertise within the cancer workforce. She attended the University of Cambridge and then Queen Mary, University of London before training in acute medicine and critical care in the east end of London which brought a strong focus on health inequalities to her practice.

### Dr Jonathan Lim

✕ @DrJonLim



Dr Jonathan Lim is currently a Crick Postdoctoral Clinical Fellow in the Cancer Dynamics Laboratory at The Francis Crick Institute. Jon completed his medical degree at St George's University of London in 2011, and commenced his career as an Academic Foundation Trainee in Brighton, before being appointed a NIHR Academic Clinical Fellow in Clinical Pharmacology and Therapeutics in Manchester. He successfully defended his PhD in Cancer Immunology in 2022 under the aegis of the Wellcome-Imperial 4i Clinical Research Fellowship at The Francis Crick Institute and Imperial College London. He also recently attained his CCT in Medical Oncology at The Christie NHS Foundation Trust in Manchester. Jon serves as a core member of the ESMO Young Oncologists Committee and ESMO Resilience Task Force, with a focus on understanding physician well-being and burnout, and finding ways to support oncology professionals globally. He is also an Associate Editor of the ESMO IOTECH journal.

### Dr Anna Mullard



Dr AP Mullard MB BCH FRCP (Medical Oncology) UK, PGCert Cancer Studies, Dip Medical Education. Consultant medical oncologist based in North Wales with sub-speciality interests in Acute oncology, Carcinoma of Unknown Primary, Germ Cell tumours, Ovarian Cancer and medical education. Setting up and running services in MUO, AOS and assessment units on a shoe string has taught her that determination and common sense will always win over resource limitation. Her greatest strengths are the team around her and the beauty of North Wales.

### Dr Anna Olsson-Brown



Anna Olsson-Brown is a Consultant in Medical Oncology. She specialises in the systemic treatment of skin cancers; immunotherapeutic toxicities, and early phase translational clinical trials. She is the Clinical Director for Acute Care at the Clatterbridge Cancer Centre, Liverpool and an Honorary Senior Lecturer at the University of Liverpool. She has a background in clinical pharmacology and an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies. She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area. She established and leads a pan-tumour, pan-regional immunotherapy toxicity service supporting inpatients and outpatients with immunotherapy toxicities. She is the current immunotherapy toxicity work stream lead for the NIHR Oncology Translational Research Committee (O-TRC) and a board member of UKASC. She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK SACT Board within this role. Within Clatterbridge she is the Chair of the Immunotherapy Committee and Deputy Chair of Supportive Care SRG. She is a current Clinical Advisor to Health Education England, Oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh, representative on the Association of Cancer Physicians and RCPE new consultant committees and senior advisor to the National Oncology Collaboration for Trainee Research (NOTCH).

### Karen Shepherd



Karen Shepherd trained as an orthopaedic surgeon within the Yorkshire rotation and commenced her consultant practice at the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry in 2008. In her formative years she trained as a therapeutic radiographer and worked at Cookridge Hospital, Leeds. She has undertaken fellowships in major trauma and limb reconstruction, as well as MSK orthopaedic oncology in the UK and abroad. Her consultant practice involves work within the soft tissue and bone sarcoma service (one of 5 in England), as well as specialising in metastatic bone disease. She is the Trust lead for metastatic bone disease, as well as being clinical lead for Palliative and End of Life Care. Looking after patients with life limiting conditions is one of her professional priorities.

Outside of work she is a mum to a teenage footballer, and wife to a football taxi driver.

### Dr Michael Tilby



Dr Michael Tilby is a Consultant Medical Oncologist at University Hospitals Coventry and Warwickshire NHS Trust. He specialises in the treatment of people with colorectal and skin cancer. He is lead clinician for acute oncology and a member of the cancer of unknown primary MDT.

Michael trained in the West Midlands and spent time out of programme as one of the National Medical Director's clinical fellows working at the Care Quality Commission (CQC). During his fellowship at the CQC Michael worked on projects focusing on urgent and emergency care across integrated care systems, supported the development of the new regulatory framework and how it might apply to medical specialities and non-surgical oncology care.

Michael has a keen interest in medical education and regularly teaches both undergraduate and postgraduate doctors in training.

### Andrew Viggars



I am a ST7 Clinical Oncology trainee in the West Yorkshire deanery. I am currently also the trainee representative on the UK acute oncology society board and have had a keen interest in acute oncology throughout training. I took an out of programme year pre-FRCR part 2 to look at service improvement in the Leeds acute oncology service and I hope to have an active role in acute oncology at the end of my training. I'm really excited to be part of the ACP weekend and seeing everyone get enthusiastic about all things acute oncology care!

### Prof Andrew Wardley



[www.linkedin.com/in/andrew-michael-wardley/](https://www.linkedin.com/in/andrew-michael-wardley/)

For those of you who don't know me, I am passionate about improving quality of and access to care for cancer patients. I recognise the need for an integrated system approach to delivering oncology services. I have, throughout my career, engaged closely and openly across all communities and professionals, developing strong collaborations and partnerships enabling improvement in a rapidly evolving cancer care domain. From conceiving, developing, and leading a fully integrated, patient focussed, research centred, holistic breast cancer service directly improving patient care and access to new treatments, from 2001 to implementation of many of these advances into services developments through commissioning initiatives locally and nationally, and contributed to international breast cancer guidelines. Indeed, the nature of cancer requires all aspects of the health system to be actively engaged to achieve desired outcomes and quality. It is important that we work closely to develop relationships with professionals, other than oncologists, involved in the delivery of cancer care. I am committed to leading innovative changes in treatments and redesigning models of cancer care across cancer systems, especially relating to systemic anti-cancer therapies.

Cancer services are in crisis. They were when I started my cancer career in 1993. Medical Oncology is an exciting and rapidly developing area. With the desire and commitment, you can all make an huge difference for your patients and colleagues. The Association of Cancer Physicians is your community. Together we can make a difference.